iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Neuropathic Pain & Epilepsy

Princeton, NJ, July 6, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has been awarded a second patent for iQure-007, its novel therapeutic currently in development for the treatment of epilepsy.

“We are delighted with this second patent being granted for iQ-007,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This is an important step in the process of commercializing this promising asset for the treatment of Drug Resistant Epilepsy. Patent protections are pivotal to maintaining the value of our assets. With the award of this second patent, we now have expanded protection and even better potential for securing market position.”

Recent experiments confirmed that iQ-007 acts as a positive allosteric modulator of naturally occurring neuromodulator EAAT2. Through this unique mechanism, it enhances the natural glutamate uptake preventing neurotoxicity, associated with epilepsy and neuropathic pain.

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma’s iQ-007 Passes Cardiac Safety Test–Critical Milestone for GLP Toxicology Studies

Princeton, NJ, June 27, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved another milestone towards IND by passing a significant cardiac safety test with iQ-007, their signature novel anti-convulsant compound.

iQure is pleased to announce that the specific affinity of iQ-007 towards the cardiac-selective binding channels, Nav1.5, Cav1.2 and hERG, were tested, and no binding was detected compared to the active reference compounds. Many anti-epileptic drugs have the potential for cardiac side effects, so it is crucial to eliminate this risk in the early stages of development. The latest results are in line with previous tests on non-selective sodium and calcium channels, which already proved negative. This shows once again the highly selective mechanism of iQ-007 as a positive allosteric modulator of the EAAT2 transporter.

"Cardiac safety is very important for a prospective medication like iQ-007, which is intended for mid- and long-term use. Here at iQure, we are mindful of how important quality of life is for patients and their families,” said iQure Chief Executive Officer, Pawel Zolnierczyk. “With these results, we can continue our efforts to advance iQ-007 to clinical trials, and ultimately offer patients an effective and safe therapy.”

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone

Princeton, NJ, May 15, 2023 ─ iQure Pharma Inc. (iQure), a US-based global biotech company, has achieved a major milestone by completing their preclinical formulation development for iQ-007, a novel anticonvulsant compound.

In the last two months, the new formulation of its lead compound iQ-007 was tested in an extensive pharmacokinetic study after oral administration in male and female rats. The results show excellent bioavailability, clear dose linearity over a large dose range from 5-400 mg/kg, and most importantly, a tripling of the elimination half-life. No gender differences were observed and based on the subsequent population analysis, this new formulation will allow the required threshold concentration to be reached within 24 hours, with a three times daily administration. Assuming a doubling of half-life in humans, which is often seen in antiepileptic drugs, this would result in a twice daily administration in the clinic trial.

“This is very good news and allows us to complete the IND-enabling package and move to the clinic development phase as soon as possible.” said iQure Chief Operating Officer, Henk de Wilde.

About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO, Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.